ResMed Q4 FY26 GAAP diluted EPS rises 2% to $2.64; revenue increases 9% to $1.46 billion

Reuters2026/08/06 20:36

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ResMed Q4 FY2026 revenue rose 9% to USD 1.46 billion from June 30, 2025 period; GAAP diluted EPS increased 2% to USD 2.64.
GAAP operating income slipped 1% to USD 448.71 million; GAAP gross margin narrowed 2 percentage points to 58.8%.
Non-GAAP diluted EPS climbed 16% to USD 2.95; non-GAAP gross margin widened 0.9 percentage points to 62.3%.
FY2026 revenue increased 10% to USD 5.65 billion; GAAP diluted EPS rose 10% to USD 10.43.
Guided to more than USD 1.85 billion of shareholder returns in FY2027; raised quarterly dividend 10% to USD 0.66.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805536) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ResMed Q4 FY26 GAAP diluted EPS rises 2% to $2.64; revenue increases 9% to $1.46 billion

You may also like

Crypto prices